Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial
- PMID: 30586721
- DOI: 10.1161/CIRCULATIONAHA.118.038201
Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial
Abstract
Background: The role of intraaortic balloon counterpulsation (IABP) in cardiogenic shock is still a subject of intense debate despite the neutral results of the IABP-SHOCK II trial (Intraaortic Balloon Pump in Cardiogenic Shock II) with subsequent downgrading in international guidelines. So far, randomized data on the impact of IABP on long-term clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction are lacking. Furthermore, only limited evidence is available on general long-term outcomes of patients with cardiogenic shock treated by contemporary practice.
Methods: The IABP-SHOCK II trial is a multicenter, randomized, open-label trial. Between 2009 and 2012, 600 patients with cardiogenic shock complicating acute myocardial infarction undergoing early revascularization were randomized to IABP versus control.
Results: Long-term follow-up was performed 6.2 years (interquartile range 5.6-6.7) after initial randomization. Follow-up was completed for 591 of 600 patients (98.5%). Mortality was not different between the IABP and the control group (66.3% versus 67.0%; relative risk, 0.99; 95% CI, 0.88-1.11; P=0.98). There were also no differences in recurrent myocardial infarction, stroke, repeat revascularization, or rehospitalization for cardiac reasons (all P>0.05). Survivors' quality of life as assessed by the EuroQol 5D questionnaire and the New York Heart Association class did not differ between groups.
Conclusions: IABP has no effect on all-cause mortality at 6-year long-term follow-up. Mortality is still very high, with two thirds of patients with cardiogenic shock dying despite contemporary treatment with revascularization therapy.
Clinical trial registration: URL: https://www.
Clinicaltrials: gov/. Unique identifier: NCT00491036.
Keywords: acute myocardial infarction; angioplasty; assist device; cardiogenic shock; intraaortic balloon counterpulsation.
Comment in
-
Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock.Circulation. 2019 Jan 15;139(3):404-406. doi: 10.1161/CIRCULATIONAHA.118.038279. Circulation. 2019. PMID: 30586784 Free PMC article. No abstract available.
-
Shifting the attention from devices to treatment: the lesson from IABP-SHOCK II and other trials in cardiogenic shock.J Thorac Dis. 2019 Nov;11(11):E206-E209. doi: 10.21037/jtd.2019.10.66. J Thorac Dis. 2019. PMID: 31903283 Free PMC article. No abstract available.
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
